2018 Q1 Form 10-K Financial Statement
#000172312818000005 Filed on March 09, 2018
Income Statement
| Concept | 2018 Q1 | 2017 Q4 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | -100.0% | -100.0% |
| Cost Of Revenue | $130.6M | $170.4M |
| YoY Change | -18.12% | -52.63% |
| Gross Profit | $144.6M | $151.4M |
| YoY Change | 24.63% | -193.87% |
| Gross Profit Margin | ||
| Selling, General & Admin | $25.12M | $64.00M |
| YoY Change | -46.66% | 11.11% |
| % of Gross Profit | 17.37% | 42.27% |
| Research & Development | $44.21M | $15.70M |
| YoY Change | 96.48% | -23.41% |
| % of Gross Profit | 30.57% | 10.37% |
| Depreciation & Amortization | $14.80M | $24.00M |
| YoY Change | -42.64% | -4.76% |
| % of Gross Profit | 10.24% | 15.85% |
| Operating Expenses | $0.00 | $0.00 |
| YoY Change | -100.0% | -100.0% |
| Operating Profit | $63.55M | $151.4M |
| YoY Change | 36.63% | -163.25% |
| Interest Expense | -$21.05M | $24.40M |
| YoY Change | 59.48% | -282.09% |
| % of Operating Profit | -33.12% | 16.11% |
| Other Income/Expense, Net | -$11.54M | -$300.0K |
| YoY Change | 787.54% | -104.76% |
| Pretax Income | $52.02M | -$310.1M |
| YoY Change | -177.06% | 14.43% |
| Income Tax | $400.0K | $0.00 |
| % Of Pretax Income | 0.77% | |
| Net Earnings | $0.00 | $0.00 |
| YoY Change | -100.0% | -100.0% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | $0.00 | $0.00 |
| Diluted Earnings Per Share | $0.00 | $0.00 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 1.000K shares | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2018 Q1 | 2017 Q4 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $48.20M | $181.8M |
| YoY Change | -69.36% | 0.94% |
| Cash & Equivalents | $48.22M | $74.17M |
| Short-Term Investments | ||
| Other Short-Term Assets | $41.70M | $53.40M |
| YoY Change | 54.44% | 190.22% |
| Inventory | $327.9M | $284.0M |
| Prepaid Expenses | ||
| Receivables | $346.7M | $351.4M |
| Other Receivables | $11.00M | $15.15M |
| Total Short-Term Assets | $0.00 | $771.9M |
| YoY Change | -100.0% | 22.32% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $489.9M | $486.8M |
| YoY Change | 103.96% | 108.55% |
| Goodwill | $26.44M | |
| YoY Change | -7.02% | |
| Intangibles | $44.60M | |
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $18.90M | $11.26M |
| YoY Change | -80.43% | -91.39% |
| Total Long-Term Assets | $0.00 | $570.0M |
| YoY Change | -100.0% | -52.18% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $0.00 | $771.9M |
| Total Long-Term Assets | $0.00 | $570.0M |
| Total Assets | $0.00 | $1.342B |
| YoY Change | -100.0% | -26.39% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $84.20M | $70.01M |
| YoY Change | 14.71% | 18.67% |
| Accrued Expenses | $129.0M | $248.1M |
| YoY Change | -44.2% | 1.39% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $75.00M | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $14.40M | $89.17M |
| YoY Change | -19.1% | 403.79% |
| Total Short-Term Liabilities | $0.00 | $296.9M |
| YoY Change | -100.0% | -7.6% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $1.392B | $1.355B |
| YoY Change | 81.96% | 66.6% |
| Other Long-Term Liabilities | $20.30M | $7.793M |
| YoY Change | -58.23% | -87.86% |
| Total Long-Term Liabilities | $1.413B | $1.421B |
| YoY Change | 73.59% | 61.85% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $0.00 | $296.9M |
| Total Long-Term Liabilities | $1.413B | $1.421B |
| Total Liabilities | $0.00 | $0.00 |
| YoY Change | -100.0% | -100.0% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$382.8M | |
| YoY Change | ||
| Common Stock | $10.00 | $10.00 |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $0.00 | $0.00 |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $0.00 | $1.342B |
| YoY Change | -100.0% | -26.39% |
Cashflow Statement
| Concept | 2018 Q1 | 2017 Q4 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | $0.00 | $0.00 |
| YoY Change | -100.0% | -100.0% |
| Depreciation, Depletion And Amortization | $14.80M | $24.00M |
| YoY Change | -42.64% | -4.76% |
| Cash From Operating Activities | $27.03M | $0.00 |
| YoY Change | -32.09% | -100.0% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $19.50M | -$2.600M |
| YoY Change | -324.13% | -85.14% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$4.400M | |
| YoY Change | -6.38% | |
| Cash From Investing Activities | -$19.50M | $0.00 |
| YoY Change | 137.79% | -100.0% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | $30.00M | |
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -$33.25M | $0.00 |
| YoY Change | -40.74% | -100.0% |
| NET CHANGE | ||
| Cash From Operating Activities | $27.03M | $0.00 |
| Cash From Investing Activities | -$19.50M | $0.00 |
| Cash From Financing Activities | -$33.25M | $0.00 |
| Net Change In Cash | -$25.31M | $0.00 |
| YoY Change | 3.29% | -100.0% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $27.03M | $0.00 |
| Capital Expenditures | $19.50M | -$2.600M |
| Free Cash Flow | $7.530M | $2.600M |
| YoY Change | -84.47% | -196.3% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q4 | us-gaap |
Assets Current
AssetsCurrent
|
0 | USD |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
0 | USD |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
0 | USD |
| CY2017 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2017 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2017 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2017 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2017 | |
| CY2017 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2017-12-31 | |
| CY2017 | dei |
Document Type
DocumentType
|
10-K | |
| CY2017 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001723128 | |
| CY2018Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
1000 | shares |
| CY2017 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
No | |
| CY2017 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
| CY2017Q2 | dei |
Entity Public Float
EntityPublicFloat
|
0 | USD |
| CY2017 | dei |
Entity Registrant Name
EntityRegistrantName
|
Atlas Holdings, Inc. | |
| CY2017 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2017 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2017Q4 | ipxl |
Convertible Common Stock Shares Issued Upon Conversion
ConvertibleCommonStockSharesIssuedUponConversion
|
1 | shares |
| CY2017Q4 | us-gaap |
Assets
Assets
|
0 | USD |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
0 | USD |
| CY2017Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
1000 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
1000 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
1000 | shares |
| CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
10 | USD |
| CY2017Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
0.00 | |
| CY2017Q4 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
0 | USD |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
0 | USD |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
0 | USD |
| CY2017Q4 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
1000 | shares |
| CY2017Q4 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2017Q4 | us-gaap |
Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
|
0 | USD |
| CY2017Q4 | us-gaap |
Liabilities
Liabilities
|
0 | USD |
| CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
0 | USD |
| CY2017Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
0 | USD |
| CY2017Q4 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
0 | USD |
| CY2017Q4 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
0 | USD |
| CY2017Q4 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
0 | USD |
| CY2017Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
0 | USD |
| CY2017Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
0 | USD |
| CY2017Q4 | us-gaap |
Operating Expenses
OperatingExpenses
|
0 | USD |
| CY2017Q4 | us-gaap |
Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock
ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock
|
10 | USD |
| CY2017Q4 | us-gaap |
Revenues
Revenues
|
0 | USD |
| CY2017 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OVERVIEW AND DESCRIPTION OF BUSINESS</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Atlas Holdings, Inc. (the “Company”, “Atlas Holdings” or following the closing of the Combination (as defined below), “New Amneal”) is a Delaware corporation and a direct wholly-owned subsidiary of Impax Laboratories, Inc. (“Impax”) that was formed by Impax for the purpose of engaging in the proposed combination of the generics and specialty pharmaceutical business of Impax with the generic drug development and manufacturing business of Amneal Pharmaceuticals, LLC (“Amneal”), pursuant to the terms of the Business Combination Agreement (the “BCA”), dated as of October 17, 2017, as amended on November 21, 2017 and December 16, 2017, by and among Impax, Amneal, the Company and K2 Merger Sub Corporation, a direct wholly owned subsidiary of the Company (“Merger Sub”) and the transactions contemplated thereby (the “Combination”). The Combination includes (i) the merger of Impax with Merger Sub, with Impax surviving the merger as a direct wholly owned subsidiary of the Company (the “Impax Merger”) (ii) the conversion of the surviving corporation of the Impax Merger into a Delaware limited liability company, (iii) the contribution by the Company of the of all of the equity interests of Impax to Amneal in exchange for certain equity interests of Amneal and (iv) the issuance by the Company of shares of its Class B Common Stock to the existing members of Amneal (the “Existing Amneal Members”). Following completion of the Combination, Atlas Holdings will be renamed Amneal Pharmaceuticals, Inc. and will become a holding company whose principal asset will be the economic interests in the combined business of Impax and Amneal. References to “New Amneal” throughout this Annual Report on Form 10-K refers to renamed company following the closing of the Combination.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has no operations and no material assets or liabilities. The Company has not carried on any activities other than those incidental to the Company’s formation and the matters contemplated by the BCA during the period from October 4, 2017, the date of the Company’s formation, to </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">1,000</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock, par value $</font><font style="font-family:inherit;font-size:10pt;">0.01</font><font style="font-family:inherit;font-size:10pt;"> per share, issued and outstanding to Impax.</font></div></div> | |
| CY2017 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of estimates - </font><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP and the rules and regulations of the U.S. Securities & Exchange Commission ("SEC") requires the use of estimates and assumptions, based on complex judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from estimated results.</font></div></div> |
